NCT07111533

Brief Summary

The aim of this study is to compare between autogenous PPG and Pericardium membrane in management of periodontal intrabody defects in stage III periodontitis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 1, 2025

Completed
Same day until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 8, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2026

Completed
Last Updated

March 16, 2026

Status Verified

March 1, 2026

Enrollment Period

5 months

First QC Date

August 1, 2025

Last Update Submit

March 13, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in Clinical Attachment Level (CAL) from Baseline to 6 Months

    The distance from the cementoenamel junction (CEJ) to the bottom of the periodontal pocket will be measured in millimeters (mm) using a UNC-15 probe. Improvement in CAL indicates periodontal healing.

    Baseline, 3 months, and 6 months

Secondary Outcomes (4)

  • Change in Probing Depth (PD) from Baseline to 6 Months

    Baseline, 3 months, and 6 months

  • Change in Plaque Index (PI) from Baseline to 6 Months

    Baseline, 3 months, and 6 months

  • Change in Gingival Index (GI) from Baseline to 6 Months

    Baseline, 3 months, and 6 months

  • Radiographic Bone Fill Measured by Cone Beam Computed Tomography (CBCT) from Baseline to 6 Months

    Baseline and 6 months

Study Arms (2)

Group I (Open Flap Debridement (OFD) with autogenous Periosteal Pedicle Graft (PPG) and Bone graft).

ACTIVE COMPARATOR

● In Group I , OFD will be performed, then a bone graft will be packed into the defect and autogenous PPG will be adapted for defect coverage as an autogenous membrane for GTR.

Procedure: Open Flap Debridement (OFD)Procedure: Bone GraftProcedure: Autogenous Periosteal Pedicle Graft (PPG)

Group II (Open Flap Debridement (OFD) with Pericardium membrane and Bone graft).

ACTIVE COMPARATOR

● In Group II , OFD will be performed, then a bone graft will be packed into the defect and a pericardium membrane was adapted for defect coverage.

Procedure: Open Flap Debridement (OFD)Procedure: Bone GraftProcedure: Pericardium Membrane

Interventions

Under Local Anesthesia , intrasulcular incisions using surgical blade #15c Then, a full thickness mucoperiosteal flap will be raised . Then, the granulation tissue in the intrabony defect will be debrided and the root will be planned using manual and ultrasonic instruments followed by saline and chlorohexidine irrigation till obtaining a healthy sound bone surface.

Group I (Open Flap Debridement (OFD) with autogenous Periosteal Pedicle Graft (PPG) and Bone graft).Group II (Open Flap Debridement (OFD) with Pericardium membrane and Bone graft).
Bone GraftPROCEDURE

Bovine Xenograft material packed into the debrided defect.

Group I (Open Flap Debridement (OFD) with autogenous Periosteal Pedicle Graft (PPG) and Bone graft).Group II (Open Flap Debridement (OFD) with Pericardium membrane and Bone graft).

* Vertical releasing incisions will be used if necessary for better access. * The periosteal membrane will be separated from this flap and released with one vertical incision mesially and one horizontal incision apically . Posteriorly, the periosteum remained attached to the mucoperiosteal flap for adequate blood supply. * periosteal membrane will be turned over to cover this defect completely and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture. \*The soft tissue flap will be sutured with 5-0 nonabsorbable prolene suture material and a periodontal dressing was given.

Group I (Open Flap Debridement (OFD) with autogenous Periosteal Pedicle Graft (PPG) and Bone graft).

A pericardium membrane was adapted for defect coverage and sutured with the lingual flap with a synthetic 6-0 bioabsorbable Vicryl suture.

Group II (Open Flap Debridement (OFD) with Pericardium membrane and Bone graft).

Eligibility Criteria

Age25 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • patients of both sexes aged (25-45) years old.
  • Patients who exhibit signs of (stage III) periodontitis.
  • Healthy individuals and free from systemic disease that may contraindicate periodontal surgery and influence the outcome of the therapy, according to the detailed questionnaire of the dental modification of the Cornell medical index .
  • Patients who have not received antibiotics or any medication for at least 6 months prior to this study.
  • Patients who have not undergone any type of Surgical periodontal therapy 6 months prior to the initial examination.
  • Patients able to return for multiple follow-up visits.

You may not qualify if:

  • Pregnant and lactating females .
  • Teeth with mobility greater than Grade I according to Miller classification .
  • Patients with any harmful habits, like smoking or tobacco chewing.
  • Unacceptable oral hygiene after the re-evaluation of phase I therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of dentistry, Minia University

Minya, Minya Governorate, 61519, Egypt

Location

MeSH Terms

Conditions

Periodontitis

Interventions

Bone Transplantation

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

Tissue TransplantationCell- and Tissue-Based TherapyBiological TherapyTherapeuticsOrthopedic ProceduresSurgical Procedures, OperativeTransplantation

Study Officials

  • Ahmed A Khalil, professor

    Minia University

    STUDY CHAIR
  • Aya Allah k Abd El-al, Lecturer

    Minia University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Demonstrator

Study Record Dates

First Submitted

August 1, 2025

First Posted

August 8, 2025

Study Start

August 1, 2025

Primary Completion

January 1, 2026

Study Completion

January 1, 2026

Last Updated

March 16, 2026

Record last verified: 2026-03

Locations